本文關(guān)鍵詞： 祛痰活血顆粒 非酒精性脂肪性肝病 FibroScan　出處：《西南醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:通過觀察祛痰活血顆粒治療非酒精性脂肪性肝病(NAFLD)痰瘀互結(jié)證型病人的腹圍和體重指數(shù),肝功和血脂,FibroScan檢測結(jié)果和腹部B超以及癥狀的變化,評價祛痰活血顆粒治療非酒精性脂肪性肝病痰瘀互結(jié)證臨床療效。方法:將84例痰瘀互結(jié)證NAFLD病人用隨機表法分成治療組和對照組,兩組各42例,治療組病人給予口服祛痰活血顆粒,對照組病人給予口服多烯磷脂酰膽堿膠囊,治療3個月,分別比較兩組病人治療前后的腹圍和體重指數(shù),肝功和血脂,FibroScan檢測結(jié)果和腹部B超以及中醫(yī)癥狀的變化。結(jié)果:(1)兩組病人的年齡、男女性別數(shù)比較無差別(P0.05),兩組可比較。兩組病人的血常規(guī)、腎功能、尿常規(guī)、大便常規(guī)、心電圖等安全指標未見異常。(2)兩組病人的腹圍和體重指數(shù)治療前后對比有差異(P0.01),具有統(tǒng)計學(xué)意義;肝功和血脂治療前后對比有差異(P0.01),具有統(tǒng)計學(xué)意義;FibroScan檢測結(jié)果以及中醫(yī)癥狀治療前后對比有差異(P0.01),具有統(tǒng)計學(xué)意義。治療后兩組病人的腹圍和體重指數(shù),肝功和血脂,FibroScan檢測結(jié)果和中醫(yī)癥狀組間比較沒有差別(P0.05)。(3)兩組病人治療前后查腹部B超提示肝臟脂肪變程度改變不顯著(P0.05),治療后組間比較肝脂肪變差別不明顯(P0.05)。結(jié)論:(1)祛痰活血顆粒治療NAFLD痰瘀互結(jié)證病人能降低病人的腹圍和體重指數(shù),使肝功、血脂恢復(fù),降低FibroScan檢測值和緩解中醫(yī)癥狀。(2)祛痰活血顆粒治療NAFLD痰瘀互結(jié)證對腹部彩超影像學(xué)改變不大,對FibroScan檢測值有較大影響,FibroScan檢測更有利用于NAFLD患者隨訪管理。(3)祛痰活血顆粒治療NAFLD痰瘀互結(jié)證總體的療效較多烯磷脂酰膽堿膠囊組優(yōu)越。(4)祛痰活血顆粒治療NAFLD痰瘀互結(jié)證療效明顯,服用方便,安全性好。
[Abstract]:Objective: to observe the abdominal circumference, body mass index (BMI), liver function and blood lipid of patients with non-alcoholic fatty liver disease (NAF LDD) treated by Quphan Huoxue granule. The results of FibroScan and the changes of abdominal B ultrasound and symptoms. Objective: to evaluate the clinical efficacy of Quphan Huoxue granule in treating non-alcoholic fatty liver disease with phlegm and blood stasis syndrome. Methods: 84 cases of NAFLD with phlegm and blood stasis syndrome were randomly divided into treatment group (n = 42) and control group (n = 42). The patients in the treatment group were given oral dispel phlegm and blood circulation granule, and the patients in the control group were treated with polyene phosphatidylcholine capsule for 3 months. The abdominal circumference and body mass index, liver function and blood lipid of the two groups were compared before and after treatment. FibroScan test results, abdominal B ultrasound and changes of TCM symptoms. Results there was no difference in age, sex between male and female patients in the two groups (P0.05). The blood routine, renal function, urine routine and stool routine were compared between the two groups. There was no significant difference in abdominal circumference and body mass index between the two groups before and after treatment (P 0.01). There was significant difference between liver function and blood lipid before and after treatment (P 0.01). The results of FibroScan and the comparison of TCM symptoms before and after treatment had statistical significance. After treatment, the abdominal circumference and body mass index, liver function and blood lipid of the two groups were significantly different. There was no difference between the results of FibroScan examination and the group of TCM symptoms. (P0.05. 3) the abdominal ultrasonography before and after treatment showed that there was no significant change in the degree of hepatic steatosis in the two groups (. P0.05). After treatment, there was no significant difference in liver fat change between the two groups. Conclusion: Quphlegm Huoxue granule can reduce the abdominal circumference and body mass index of patients with NAFLD syndrome of phlegm and blood stasis and make liver function. Blood lipids recovery, reduce FibroScan detection value and alleviate the symptoms of traditional Chinese medicine. 2) Quphlegm Huoxue granule treatment of NAFLD phlegm and blood stasis syndromes has little change in abdominal color ultrasound imaging. It has great influence on the detection value of FibroScan. FibroScan detection is more favorable for NAFLD patients follow up management. 3) Quphlegm Huoxue granule treatment of NAFLD phlegm and blood stasis syndromes overall curative effect is superior to that of multiene phosphatidylcholine capsule group. 4) expelling phlegm and activating blood granule in treating NAFLD syndrome of phlegm and blood stasis is obvious. Easy to take and safe.
【學(xué)位授予單位】：西南醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R259

【參考文獻】

相關(guān)期刊論文 前10條

1 彭孟云;朱曉寧;汪靜;;非酒精性脂肪肝從痰瘀論治[J];中國中醫(yī)藥現(xiàn)代遠程教育;2016年22期

2 許勇;陶穎;茍小軍;;非酒精性脂肪肝中醫(yī)病因病機探析[J];中華中醫(yī)藥學(xué)刊;2016年11期

3 陳建能;陳愛萍;潘勤;郭其裕;沈峰;鄭瑞丹;范建高;;FibroScan~實施受控衰減參數(shù)檢測肝脂肪變的影響因素及應(yīng)用價值分析[J];肝臟;2016年10期

4 常彬霞;李保森;鄒正升;;《2016年歐洲肝病學(xué)會、歐洲糖尿病學(xué)會和歐洲肥胖學(xué)會臨床實踐指南:非酒精性脂肪性肝病》摘譯[J];臨床肝膽病雜志;2016年08期

5 史曉偉;王一強;張玉香;王俊喹;;清肝祛濕活血方治療非酒精性脂肪肝的療效評價[J];中國實驗方劑學(xué)雜志;2016年15期

6 竇慧馨;張得鈞;;酒精性肝病分子發(fā)病機制研究進展[J];基因組學(xué)與應(yīng)用生物學(xué);2016年07期

7 溫博;王炳元;李靜波;劉姝;高楠;王穎;;Fibrotouch與超聲診斷脂肪肝一致性分析[J];中國肝臟病雜志(電子版);2016年02期

8 王雁翔;臧金旺;傅志泉;張金峰;曹紅燕;;強化行為干預(yù)結(jié)合補腎益脾法治療非酒精性脂肪性肝炎的臨床研究[J];中西醫(yī)結(jié)合肝病雜志;2016年02期

9 徐中菊;王慧;顧婷婷;陳寶瑾;陳雄白;;丹芍疏肝顆粒對不同中醫(yī)證型非酒精性脂肪肝臨床療效研究[J];遼寧中醫(yī)雜志;2016年04期

10 李靜波;劉姝;溫博;高楠;王炳元;;FibroTouch與B超、CT對脂肪肝的診斷價值比較[J];臨床肝膽病雜志;2016年03期

相關(guān)博士學(xué)位論文 前1條

1 徐婉倫;基于數(shù)據(jù)挖掘的中藥治療非酒精性脂肪肝臨床用藥規(guī)律與特色[D];南京中醫(yī)藥大學(xué);2015年

，

本文編號：1445092